{"id":"mw032","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"},{"rate":null,"effect":"Infusion reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MW032 binds to programmed death ligand 1 (PD-L1) on tumor cells and immune cells, preventing engagement with PD-1 and B7-1 receptors on T cells. This blockade reverses T cell exhaustion and restores anti-tumor immunity, allowing the immune system to recognize and eliminate cancer cells more effectively.","oneSentence":"MW032 is a monoclonal antibody targeting PD-L1 to enhance anti-tumor immune responses by blocking the interaction between PD-L1 and PD-1/B7-1.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:22:25.171Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Other solid tumors (under investigation)"}]},"trialDetails":[{"nctId":"NCT02470091","phase":"PHASE2","title":"Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2015-11-21","conditions":"Metastatic Osteosarcoma, Recurrent Osteosarcoma, Refractory Osteosarcoma","enrollment":56},{"nctId":"NCT04812509","phase":"PHASE3","title":"Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors","status":"COMPLETED","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2020-03-20","conditions":"Bone Metastases","enrollment":708},{"nctId":"NCT03382574","phase":"EARLY_PHASE1","title":"Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-03-14","conditions":"Ovarian Carcinoma","enrollment":2},{"nctId":"NCT04798326","phase":"PHASE1","title":"Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW032 and Xgeva® in Healthy Adults","status":"COMPLETED","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2019-06-25","conditions":"Bone Tumor","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["recombinant human anti-RANKL monoclonal antibody injection"],"phase":"phase_3","status":"active","brandName":"MW032","genericName":"MW032","companyName":"Mabwell (Shanghai) Bioscience Co., Ltd.","companyId":"mabwell-shanghai-bioscience-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MW032 is a monoclonal antibody targeting PD-L1 to enhance anti-tumor immune responses by blocking the interaction between PD-L1 and PD-1/B7-1. Used for Non-small cell lung cancer, Other solid tumors (under investigation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}